t
| Date | 29 Mar 2022 |
| Time | 08:00:03 |
| Category | Corporate updates |
| ID | 3693G |
29 March 2022
Celadon Pharmaceuticals Plc
("Celadon" or the "Company")
Change of name
Further to yesterday's announcement, the Company confirms that, the change of name from Summerway Capital plc to Celadon Pharmaceuticals Plc, is effective on the London Stock Exchange as of today.
As a result, the Company's stock market ticker is now CEL and its ISIN and SEDOL remain unchanged. The change of name will not affect any rights of shareholders and existing share certificates should be retained as they will remain valid and no new share certificates will be issued.
Enquiries:
|
Celadon Pharmaceuticals Plc |
|
|
Mo Noonan |
078 764 44977 |
|
|
|
|
Canaccord Genuity Limited (Nominated Adviser and Broker) |
|
|
Andrew Potts / Patrick Dolaghan |
020 7523 800 |
About Celadon Pharmaceuticals Plc
Celadon Pharmaceuticals Plc is a UK based pharmaceutical company targeting the research, cultivation, manufacturing and supply of cannabinoid-based medicines. Its primary focus is on improving quality of life for chronic pain sufferers, as well as exploring the potential of cannabinoid-based medicines for other conditions such as autism. Its UK facility comprises a laboratory designed to meet UK-GMP standards, and capacity for a large indoor hydroponic growing facility that has received a Home Office Licence to legally grow high THC medicinal cannabis for the purpose of producing test batches of cannabis oil to support its application to the MHRA. The Company's subsidiary, LVL, owns a MHRA conditionally approved cannabis trial using cannabis based medicinal products to treat chronic pain in the UK.
For further information please visit our website www.celadonpharma.com